Dermatofibrosarcoma protuberans: A partial response to imatinib therapy

Dermatologic Surgery

Volumn 32, Issue 3, 2006, Pages 456-459

  Mehrany, Khosrow ^a   Swanson, Neil A ^a   Heinrich, Michael C ^a,b,c   Weenig, Roger H ^d   Lee, Ken K ^a   White Jr , Clifton R ^a   Devere, Theresa S ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b Health and Sciences Center   (United States)

^c PORTLAND VA MEDICAL CENTER   (United States)

^d MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; IMATINIB;

ADULT; ARTICLE; CANCER IMMUNOTHERAPY; CASE REPORT; CHEMOSURGERY; CHROMOSOME ABERRATION; CLINICAL FEATURE; CLINICAL TRIAL; DERMATOFIBROSARCOMA PROTUBERANS; DIAGNOSTIC IMAGING; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; ESTHETICS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MUSCLE FUNCTION; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PUNCH BIOPSY; TUMOR VOLUME;

ANTINEOPLASTIC AGENTS; CHEEK; DERMATOFIBROSARCOMA; FACIAL NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PYRIMIDINES; SKIN NEOPLASMS;

EID: 33645457360     PISSN: 10760512     EISSN: 15244725     Source Type: Journal    
DOI: 10.1111/j.1524-4725.2006.32090.x     Document Type: Article

References (14)

1. Gloster HM Jr.. Dermatofibrosarcoma protuberans. J Am Acad Dermatol 1996 35 355 74. Erratum in: J Am Acad Dermatol 1997;36:526.
2. Nouri K Lodha R Jimenez G Robins P. Mohs micrographic surgery for dermatofibrosarcoma protuberans university of Miami and NYU experience. Dermatol Surg 2002 28 1060 4.
3. Taylor HB Helwig EB. Dermatofibrosarcoma protuberans a study of 115 cases. Cancer 1962 15 717 25.
4. McPeak CJ Cruz T Nicastri AD. Dermatofibrosarcoma protuberans an analysis of 86 cases - five with metastasis. Ann Surg 1967 166 803 16.
5. Rinck PA Habermalz HJ Lobeck H. Effective radiotherapy in one case of dermatofibrosarcoma protuberans. Strahlentherapie 1982 158 681 5.
6. Wrotnowski U Cooper PH Shmookler BM. Fibrosarcomatous change in dermatofibrosarcoma protuberans. Am J Surg Pathol 1988 12 287 93.
7. Sirvent N Maire G Pedeutour F. Genetics of dermatofibrosarcoma protuberans family of tumors from ring chromosomes to tyrosine kinase inhibitor treatment. Genes Chromosomes Cancer 2003 37 1 19.
8. Sjoblom T Shimizu A O'Brien KP et al. Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Res 2001 61 5778 83.
9. Shimizu A O'Brien KP Sjoblom T et al. The dermatofibrosarcoma protuberans-associated collagen type Iα1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB. Cancer Res 1999 59 3719 23.
10. Buchdunger E O'Reilly T Wood J. Pharmacology of imatinib (STI571). Eur J Cancer 2002 38 Suppl 5 S28 36.
11. Manley PW Cowan-Jacob SW Buchdunger E et al. Imatinib a selective tyrosine kinase inhibitor. Eur J Cancer 2002 38 Suppl 5 S19 27.
12. Greco A Roccato E Miranda C Cleris L Formelli F Pierotti MA. Growth-inhibitory effect of STI571 on cells transformed by the COL1A1/platelet-derived growth factor B rearrangement. Int J Cancer 2001 92 354 60.
13. Maki RG Awan RA Dixon RH Jhanwar S Antonescu CR. Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans. Int J Cancer 2002 100 623 6.
14. Rubin BP Schuetze SM Eary JF et al. Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J Clin Oncol 2002 20 3586 91.